StockNews.com downgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a hold rating to a sell rating in a report published on Friday.

Several other research firms have also recently weighed in on CGEN. Truist Financial cut their price target on shares of Compugen from $14.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, August 23rd. Oppenheimer decreased their target price on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a research report on Monday, August 8th. Jefferies Financial Group downgraded shares of Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Finally, JMP Securities reduced their target price on shares of Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a research report on Monday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $6.20.

Compugen Price Performance

Shares of Compugen stock opened at $1.04 on Friday. Compugen has a one year low of $0.99 and a one year high of $7.48. The stock's 50-day moving average is $1.57 and its 200 day moving average is $2.13. The firm has a market cap of $90.09 million, a price-to-earnings ratio of -2.67 and a beta of 2.15.

Institutional Trading of Compugen

Several institutional investors and hedge funds have recently bought and sold shares of CGEN. Raymond James & Associates boosted its stake in Compugen by 5.4% during the fourth quarter. Raymond James & Associates now owns 213,510 shares of the biotechnology company's stock valued at $918,000 after buying an additional 11,015 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Compugen during the 4th quarter valued at about $1,760,000. Virtus ETF Advisers LLC grew its holdings in shares of Compugen by 60.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 40,161 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 15,182 shares in the last quarter. PDT Partners LLC grew its stake in Compugen by 55.9% in the 4th quarter. PDT Partners LLC now owns 220,083 shares of the biotechnology company's stock worth $946,000 after buying an additional 78,883 shares in the last quarter. Finally, Antonetti Capital Management LLC increased its holdings in shares of Compugen by 7.6% in the 4th quarter. Antonetti Capital Management LLC now owns 247,900 shares of the biotechnology company's stock worth $1,066,000 after buying an additional 17,582 shares during the last quarter.

Compugen Company Profile

(Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

See Also

• Get a free copy of the StockNews.com research report on Compugen (CGEN)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.